Background -Inhalation of sulphur dioxide (SO2) provokes bronchoconstriction in asthmatic subjects. Cholinergic mechanisms contribute, but other mechanisms remain undefined. The effect of morphine, an opioid agonist, on the cholinergic component ofS02-induced bronchoconstriction was investigated, and the effect of indomethacin, a cyclooxygenase inhibitor, on S02-induced bronchoconstriction and tachyphylaxis was studied. Methods -In the first study 16 asthmatic subjects inhaled either ipratropium bromide or placebo 60 minutes before an SO2 challenge on days 1 and 2. On day 3 an SO2 challenge was performed immediately after intravenous morphine. In the second study 15 asthmatic subjects took either placebo or indomethacin for three days before each study day when two SO2 challenges were performed 30 minutes apart. The response was measured as the cumulative dose causing a 35% fall in specific airways conductance (sGaw; PDsGaw35). Results -Ipratropium bromide significantly inhibited SO2 responsiveness, reducing PDsGaw35 by 0-89 (95% CI 0-46 to 1.31) doubling doses. This effect persisted after correction for bronchodilatation induced by ipratropium bromide. The effect of ipratropium bromide and morphine on SO2 responsiveness also correlated (r2 = 0.71). In the second study SO2 tachyphylaxis developed with PDsGaw35 on repeated testing, being reduced by 0*62 (95% CI 0*17 to 1-07) doubling doses. Indomethacin attenuated baseline SO2 responsiveness, increasing PDsGaw35 by 0.5 (95% CI 0-06 to 0.93) doubling doses. Conclusions -These results suggest that opioids modulate the cholinergic component of SO2 responsiveness and that cyclooxygenase products contribute to the immediate response to SO2.
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Methods

SUBJECTS
Thirty one subjects with mild asthma gave their informed consent to take part in these studies which were approved by the Royal North Shore Hospital ethics committee. All had a prechallenge forced expiratory volume in one second (FEVy) of at least 70% of their predicted value, no subject had had a respiratory tract infection for six weeks before testing, all were non-smokers, and all had previously demonstrated bronchial hyperresponsiveness to SO2. Inhaled sympathomimetics were withheld for six hours or more before testing, but during testing all other inhaled therapy was maintained at a constant rate.
STUDY PROTOCOLS
Opioid study This study involved three visits which were completed within four weeks. All tests were performed at the same time of day (12.00 to 16.00 hours), but any two consecutive tests were separated by at least 48 hours. 400-1000 jtg/day) and all took an inhaled 12 agonist as required. No subject developed bronchoconstriction after inhaling the control partially humidified air for three minutes. The baseline sGaw was similar in each study (table 1) and did not change significantly after administration of placebo and morphine, but after iprat-opium bromide there was a significant increase in sGaw (p<005). However, the degree of bronchodilatation induced by ipratropium bromide and the effect of ipratropium bromide on 82 airways responsiveness (R2=0029) were not significantly correlated.
Ipratropium bromide attenuated S02 responsiveness. The placebo geometric mean PDsGaw35 of 2-97 ppm increased to 5 50 ppm after ipratropium bromide, a mean difference of 0-89 (95% CI 0-46 to 1-31) doubling doses (p<00005) (fig 1) . The effects of ipratropium bromide and morphine on S02 PDsGaw35 were significantly correlated (R2 = 0-71, p<0*0001) Morphine log PDsGaw35 (ppm) Figure 2 Comparison of the effect of ipratropium bromide (IPB) and the ef] on airway responsiveness to sulphur dioxide (SO2) in 16 mild asthmatic subje Baseline airway calibre before SO2 challenges on the placebo and indomethacin study days did not differ significantly. On the placebo day the mean sGaw before the first and second S02 challenges were 0-14 (0-02) and 0-14 (0-16) s-' cm H20-1, respectively. On the indomethacin day the mean sGaw before the first and second S02 challenges were both 0 14 (0 02) s-'cm H20-1l S02 tachyphylaxis was measured after administration of placebo (table 2) . On the placebo day the first and second challenge The attenuation of initial SO2 responsiveness by indomethacin suggests that the airway response tO SO2 iS partially mediated by cyclooxygenase products present in the airways of asthmatic subjects. However, this effect of indomethacin on initial SO2 responsiveness confounded interpretation of the effect of indomethacin on the development of SO2 tachyphylaxis. After indomethacin the mean change in SO2 responsiveness between the first and second challenge was significantly less than after placebo. This difference may have been due solely to the change in initial SO2 responsiveness induced by indomethacin, but it may also have reflected an inhibition of the development of SO2 tachyphylaxis by indomethacin.
The effect of indomethacin in attenuating airways responsiveness to SO2 was small, indicating that cyclooxygenase products are likely to play a minor role. The dose of indomethacin administered should have provided adequate inhibition of prostanoid production, as similar doses have been effective in inhibiting allergeninduced bronchoconstriction9 and in attenuating histamine tachyphylaxis'0 in asthmatic subjects. At the dose used in this study the production of prostaglandins is suppressed on average by more than 70%,'9 but between subjects there is considerable variation in plasma levels following a given dose. ' In conclusion, the airway response to SO2 involves the release of inflammatory mediators.
In addition, the parasympathetic reflexes which play a part in the SO2-induced bronchoconstriction have the potential to be modulated by opioids.
